2例吡非尼酮治疗新型冠状病毒肺炎后肺纤维化的疗效分析

doi:10.13418/j.issn.1001-165x.2024.3.15

PDF(3940 KB)

中国临床解剖学杂志 ›› 2024, Vol. 42 ›› Issue (3) : 331-335. DOI: 10.13418/j.issn.1001-165x.2024.3.15

临床研究

2例吡非尼酮治疗新型冠状病毒肺炎后肺纤维化的疗效分析

王霞，李家意，卢惠芬，崔海燕*

作者信息 +

Effect of pirfenidone on pulmonary interstitial fibrosis after COVID-19 in 2 cases

Wang Xia, Li Jiayi, Lu Huifen, Cui Haiyan*

Author information +

文章历史 +

摘要

目的观察并分析吡非尼酮治疗新冠病毒肺炎后肺纤维化的疗效。方法收集我院2例重型新冠肺炎后肺间质纤维化患者就诊的临床资料，分析吡非尼酮运用于抗新冠肺炎后纤维化治疗的疗效。结果 2例分别患者经吡非尼酮治疗15周和9周后，动态复查胸部CT显示两例患者肺纤维化程度均较前明显减轻。结论吡非尼酮可能在改善新冠病毒肺炎后肺纤维化预后方面具有一定疗效，但仍需更长时间的随访及更大样本的临床研究加以明确。

Abstract

Objective To observe and analyze the therapeutic effect of pirfenidone on pulmonary interstitial fibrosis secondary to COVID-19. Methods Clinical data of 2 patients with pulmonary interstitial fibrosis after severe COVID-19 were collected and followed up after discharged from our hospital, and the therapeutic effect of pirfenidone on anti-fibrosis secondary to COVID-19 was analyzed. Results After the two patients were treated with pirfenidone for 15 weeks and 9 weeks respectively, dynamic review of chest CT showed that the degree of pulmonary fibrosis in both patients was significantly reduced. Conclusions Pirfenidone may be effective in improving pulmonary fibrosis after COVID-19, but it still needs to be confirmed by longer duration of follow-up and clinical studies with more samples.

导出引用

王霞, 李家意, 卢惠芬, 崔海燕. 2例吡非尼酮治疗新型冠状病毒肺炎后肺纤维化的疗效分析[J]. 中国临床解剖学杂志. 2024, 42(3): 331-335 https://doi.org/10.13418/j.issn.1001-165x.2024.3.15

Wang Xia, Li Jiayi, Lu Huifen, Cui Haiyan. Effect of pirfenidone on pulmonary interstitial fibrosis after COVID-19 in 2 cases[J]. Chinese Journal of Clinical Anatomy. 2024, 42(3): 331-335 https://doi.org/10.13418/j.issn.1001-165x.2024.3.15

中图分类号： R563.1

参考文献

[1] Fabbri L, Moss S, Khan FA, et al. Parenchymal lung abnormalities following hospitalisation for COVID-19 and viral pneumonitis: a systematic review and meta-analysis[J]. Thorax, 2023,78(2):191-201. DOI: 10.1136/thoraxjnl-2021-218275.
[2] Remmelink M, De Mendonça R, D'Haene N, et al. Unspecific post-mortem findings despite multiorgan viral spread in COVID-19 patients[J]. Crit Care, 2020, 24(1): 495. DOI: 10.1186/s13054-020-03218-5.
[3] Hirawat R, Jain N, Aslam SM, et al. Lung fibrosis: Post-COVID-19 complications and evidences[J]. Int Immunopharmacol, 2023,116:109418. DOI: 10.1016/j.intimp.2022.109418.
[4] Boshra MS, Abou WA, Sayed MA, et al. Effect of Pirfenidone on Risk of Pulmonary Fibrosis in COVID-19 Patients Experiencing Cytokine Storm[J]. Healthcare (Basel), 2022,10(12). DOI: 10.3390/healthcare10122387.
[5] Zhou X, Yang D, Kong X, et al. Case Report: Pirfenidone in the Treatment of Post-COVID-19 Pulmonary Fibrosis[J]. Front Med (Lausanne), 2022,9:925703. DOI: 10.3389/fmed.2022.925703.
[6] John AE, Joseph C, Jenkins G, et al. COVID-19 and pulmonary fibrosis: A potential role for lung epithelial cells and fibroblasts[J]. Immunol Rev, 2021,302(1):228-240. DOI: 10.1111/imr.12977.
[7] Zhang C, Wu Z, Li JW, et al. Discharge may not be the end of treatment: Pay attention to pulmonary fibrosis caused by severe COVID-19[J]. J Med Virol, 2021,93(3):1378-1386. DOI: 10.1002/jmv.26634.
[8] Carsana L, Sonzogni A, Nasr A, et al. Pulmonary post-mortem findings in a series of COVID-19 cases from northern Italy: a two-centre descriptive study[J]. Lancet Infect Dis, 2020,20(10):1135-1140. DOI: 10.1016/S1473-3099(20)30434-5.
[9] Kerget B, Çil G, Araz Ö, et al. Comparison of two antifibrotic treatments for lung fibrosis in post-COVID-19 syndrome: A randomized, prospective study[J]. Med Clin (Barc), 2023,160(12):525-530. DOI: 10.1016/j.medcli.2022.12.021.
[10]Lancaster LH, de Andrade JA, Zibrak JD, et al. Pirfenidone safety and adverse event management in idiopathic pulmonary fibrosis[J]. Eur Respir Rev, 2017, 26(146). DOI: 10.1183/16000617.0057-2017.
[11]中华人民共和国国家卫生健康委员会. 新型冠状病毒感染诊疗方案(试行第十版)[J]. 中华临床感染病杂志, 2023(1):1-9. DOI: 10.3760/cma.j.issn.1674-2397.2023.01.001
[12]Sansores RH, Ramírez-Venegas A, Montiel-Lopez F, et al. Prolonged-release pirfenidone in patients with pulmonary fibrosis as a phenotype of post-acute sequelae of COVID-19 pneumonia. Safety and efficacy[J]. Respir Med, 2023, 217:107362. DOI: 10.1016/j.rmed.2023.107362.
[13]Bocchino M, Rea G, Capitelli L, et al. Chest CT Lung Abnormalities 1 Year after COVID-19: A Systematic Review and Meta-Analysis[J]. Radiology, 2023, 308(1): e230535. DOI: 10.1148/radiol.230535.
[14]Al-Kuraishy HM, Batiha GE, Faidah H, et al. Pirfenidone and post-Covid-19 pulmonary fibrosis: invoked again for realistic goals[J]. Inflammopharmacology, 2022,30(6):2017-2026. DOI: 10.1007/s10787-022-01027-6.
[15]Kayarat B, Khanna P, Sarkar S. Pulmonary Fibrosis in COVID-19 Recovered Patients: Problem and Potential Management[J]. Indian J Crit Care Med, 2021,25(2):242-244. DOI: 10.5005/jp-journals-10071-23733.
[16]Ferrara F, Granata G, Pelliccia C, et al. The added value of pirfenidone to fight inflammation andfibrotic state induced by SARS-CoV-2 : Anti-inflammatory and anti-fibrotic therapy could solve the lung complications of the infection?[J]. Eur J Clin Pharmacol, 2020,76(11):1615-1618. DOI: 10.1007/s00228-020-02947-4.
[17]George PM, Wells AU, Jenkins RG. Pulmonary fibrosis and COVID-19: the potential role for antifibrotic therapy[J]. Lancet Respir Med, 2020,8(8):807-815. DOI: 10.1016/S2213-2600(20)30225-3.